Verana Health Launches Qdata® Cataracts, the Largest Dataset of Its Kind for Cataract Research
Exclusive real-world insights on more than 9 million de-identified cataract surgery patients aims to advance clinical research, treatment optimization, and patient outcomes
SAN FRANCISCO, April 24, 2025 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today announced the launch of Qdata® Cataracts, the most comprehensive dataset available on cataract surgery outcomes. Derived from more than 9 million de-identified cataract surgery patients, with an average of nearly 4 years of follow-up, this research-ready dataset offers unparalleled insights into patient demographics, clinical characteristics, and treatment pathways to support drug and treatment development.
Qdata® Cataracts is powered by exclusive electronic health record (EHR) data from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), the world's largest specialty society clinical data registry. The dataset includes key variables from unstructured clinician notes and semi-structured fields of EHRs that are extracted using proprietary artificial intelligence techniques. Those variables include visual acuity, intraocular pressure (IOP) reading, and intraocular lens brand and model. A variable in development is femtosecond laser-assisted cataract surgery (FLACS). Qdata Cataracts provides critical real-world evidence (RWE) to inform clinical development, health economics and outcomes research (HEOR), and commercialization strategies.
Cataracts, a condition in which the eye’s lens becomes clouded, are a leading cause of vision impairment, often developing slowly and progressively impacting sight. Cataract surgery is one of the most common and successful medical procedures, with about 3 million surgeries performed in the U.S. each year.
“While cataract surgery is highly successful, real-world insights into surgical outcomes, lens selection, and patient experiences remain fragmented,” said Sujay Jadhav, CEO of Verana Health. “Qdata® Cataracts delivers a new level of clarity, equipping life sciences companies with high-quality evidence to advance clinical research, improve outcomes, reduce complications, and enhance intraocular lens technology.”
Qdata® Cataracts enables cohort identification, patient stratification, and real-world outcomes analysis that go beyond what claims data alone can provide. The dataset allows life sciences companies to evaluate post-surgical outcomes, patient responses to different intraocular lens models, and treatment effectiveness in clinical practice. Qdata Cataracts supports a range of applications, including identifying practices treating cataract patients for clinical trial optimization, assessing treatment patterns and patient outcomes for HEOR initiatives, and refining market insights for commercialization efforts.
For more information on Qdata Cataracts and Verana Health’s Ophthalmology Qdata collection, visit: https://veranahealth.com/products/ophthalmology-qdata/
About Verana Health
Verana Health® is a digital health company revolutionizing patient care and clinical research by utilizing physician expertise and artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world’s largest patient data sources in ophthalmology, urology, and neurology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care and quality of life for patients, and life sciences companies rely on the insights to accelerate the development of new therapies. For more information, visit www.veranahealth.com.
CONTACT: Media Contact: MikeWorldWide 847.224.6462 veranahealth@mww.com
